CAS 193217-39-9

1-Piperidinecarboxylic acid, 4-benzoyl-, 1,1-dimethylethyl ester

Description:

1-Piperidinecarboxylic acid, 4-benzoyl-, 1,1-dimethylethyl ester, identified by CAS number 193217-39-9, is an organic compound characterized by its ester functional group, which is formed from the reaction of a carboxylic acid and an alcohol. This compound features a piperidine ring, a six-membered nitrogen-containing heterocycle, which contributes to its basicity and potential for forming hydrogen bonds. The presence of the benzoyl group enhances its aromatic character, potentially influencing its reactivity and solubility in organic solvents. The tert-butyl ester group provides steric hindrance, which can affect the compound's reactivity and stability. Typically, such esters are utilized in organic synthesis and may serve as intermediates in the production of pharmaceuticals or agrochemicals. The compound's physical properties, such as melting point, boiling point, and solubility, would depend on its molecular structure and the interactions between its functional groups. Overall, this compound exemplifies the complexity and versatility of organic molecules in chemical applications.

Formula: C₁₇H₂₃NO₃

tert-Butyl 4-benzoylpiperidine-1-carboxylate

CAS: 193217-39-9

Formula: C₁₇H₂₃NO₃

Purity: 96%

Color and Shape: Solid

Molecular weight: 289.3694

Ref: IN-DA0073GM

tert-Butyl 4-benzoylpiperidine-1-carboxylate

CAS: 193217-39-9

tert-Butyl 4-benzoylpiperidine-1-carboxylate

Purity: 98%

Molecular weight: 289.375g/mol

Ref: 54-OR74978

Fexofenadine Impurity 19

CAS: 193217-39-9

Formula: C₁₇H₂₃NO₃

Molecular weight: 289.38

Ref: 4Z-F-0431

tert-Butyl 4-benzoylpiperidine-1-carboxylate

CAS: 193217-39-9

Formula: C₁₇H₂₃NO₃

Purity: 98%

Color and Shape: Solid, White to cream or yellow solid

Molecular weight: 289.375

Ref: 10-F237052

tert-Butyl 4-benzoylpiperidine-1-carboxylate

CAS: 193217-39-9

Tert-butyl 4-benzoylpiperidine-1-carboxylate (TBCPC) is a novel amide antagonist that has been shown to inhibit HIV entry into cells. TBCPC has been shown to have an oral bioavailability of 100% and a half-life of 10 hours in rats. This compound also had no effect on the pharmacokinetic profile of other drugs, which could make it a good candidate for replacing other anti-HIV drugs. TBCPC has the potential to be developed as a ccr5 antagonist and may have potential applications in treating diseases such as cancer, inflammatory bowel disease, and AIDS.

Formula: C₁₇H₂₃NO₃

Purity: Min. 95%

Molecular weight: 289.37 g/mol

Ref: 3D-THA21739